Clinical Decision-Making
CHA2DS2-VASc: Why the Same Number Can Mean Different Things
Editorial record
This source-linked educational article has been updated through AI-assisted evidence checks and editorial review. Verify information against current guidance and local protocols before applying it to patient care.
Citation methodologyA stroke-risk score starts an anticoagulation discussion; it does not select a drug, a dose, or an emergency reversal plan. This guide addresses established clinical atrial fibrillation (AF), not an isolated smartwatch notification or a short device-detected atrial episode.
Count Once, Then Name the Framework
CHA2DS2-VASc assigns one point each for heart failure, hypertension, diabetes, vascular disease, age 65-74, and female sex, and two each for age 75 or older and previous stroke, TIA, or systemic embolism. The two age bands are mutually exclusive. Its maximum is nine, not ten. The original validation was a risk-prediction study, not a trial of prescribing at each score. Original Euro Heart Survey study.
The 2023 US guideline recommends anticoagulation at estimated annual thromboembolic risk of at least 2%, exemplified by CHA2DS2-VASc of at least two in men or three in women. At intermediate estimated risk, roughly 1% to less than 2% annually, anticoagulation is reasonable after discussion. These are decision thresholds, not a promise that every score of two carries an identical event rate. Bleeding scores should help identify risks to address, not independently veto anticoagulation. Mechanical valves and moderate-or-greater mitral stenosis require a different anticoagulant pathway. US AF guideline.
The 2024 European guideline instead uses CHA2DS2-VA, omitting sex: consider anticoagulation at one and recommend it at two or more. Do not apply that threshold to a number calculated with the sex point still included. ESC AF guideline.
Worked Comparison
These are fictional examples with no other score factors:
| Person with clinical AF | CHA2DS2-VASc | CHA2DS2-VA |
|---|---|---|
| Woman aged 68 | Age 1 + sex 1 = 2 | Age 1 = 1 |
| Man aged 68 with hypertension | Age 1 + hypertension 1 = 2 | 2 |
Both have a VASc score of two, but the first example is an intermediate-risk discussion under the US framework; the second reaches its usual recommended threshold. The European framework reaches a corresponding distinction without a sex point. Record the components and guideline, not merely "score 2."
Do Not Turn This Into a Drug Table
Kidney function, interactions, valve disease, bleeding history, and the jurisdiction's current product label matter before prescribing. Even reversal availability changes: the FDA reported that Andexxa would no longer be manufactured for or sold in the US after December 22, 2025; its original indication concerned apixaban and rivaroxaban, not edoxaban. A static list of reversal agents can therefore be misleading. FDA safety communication.
For follow-up after rhythm treatment, see AF management after the score.